Roche Holding AG
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-21.2% vs price
Base Case (Median)
40.2% vs price
Bull Case (75th pct.)
62.6% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $842.12 | 102.0% | High (40%) |
| PE Comparable | $584.48 | 40.2% | Medium (25%) |
| Growth Trajectory DCF | $677.65 | 62.6% | Medium (20%) |
| Graham Number | $158.77 | -61.9% | Medium (40%) |
| EV/EBITDA | $284.77 | -31.7% | Medium (20%) |
| EV/FCF | $677.42 | 62.5% | Medium (20%) |
| Earnings Power Value | $372.37 | -10.7% | Medium (50%) |
Based on 7 out of 8 methods, RHHBF appears fairly valued at the current price of $416.80. The base case fair value of $584.48 implies 40.2% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.